Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001104659-25-062607
Filing Date
2025-06-25
Accepted
2025-06-25 16:39:53
Documents
9

Document Format Files

Seq Description Document Type Size
1 FORM S-3 tm2518806d1_s3.htm S-3 201710
2 EXHIBIT 5.1 tm2518806d1_ex5-1.htm EX-5.1 10676
3 EXHIBIT 23.2 tm2518806d1_ex23-2.htm EX-23.2 2714
4 EX-FILING FEES tm2518806d1_ex-filingfees.htm EX-FILING FEES 14734
5 GRAPHIC tm2518806d1_ex5-1img001.jpg GRAPHIC 10388
6 GRAPHIC tm2518806d1_ex5-1img002.jpg GRAPHIC 9846
7 GRAPHIC tm2518806d1_ex5-1img003.jpg GRAPHIC 4863
8 GRAPHIC tm2518806d1_s3img001.jpg GRAPHIC 4561
9 GRAPHIC tm2518806d1_s3img002.jpg GRAPHIC 4541
  Complete submission text file 0001104659-25-062607.txt   279127
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-288322 | Film No.: 251074115
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)